Overview

* Alector Q3 2025 revenue beats analyst expectations despite a year-over-year decline

* Net loss for Q3 2025 narrows compared to the same period last year

* Company implements 47% workforce reduction to focus on high-priority programs

Outlook

* Company anticipates collaboration revenue between $13 mln and $18 mln for 2025

* Alector ( ALEC ) targets IND filing for AL137 in 2026

* Independent interim analysis for PROGRESS-AD trial planned for 1H 2026

Result Drivers

* ABC PLATFORM - Alector's ( ALEC ) focus on its proprietary Alector Brain Carrier platform is driving innovation in neurodegenerative disease therapies, per CEO Arnon Rosenthal

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $3.26 $3.02

Revenue mln mln (6

Analysts

)

Q3 EPS -$0.34

Q3 Net -$34.67

Income mln

Q3 Basic -$0.34

EPS

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Alector Inc ( ALEC ) is $1.50, about 16.3% above its November 5 closing price of $1.26

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)